<DOC>
	<DOCNO>NCT01557023</DOCNO>
	<brief_summary>This trial study percentage woman least one occurrence intracyclic bleeding ( bleed and/or spot ) cycle 2 3 treatment test reference drug .</brief_summary>
	<brief_title>Clinical Trial With Combination Dienogest/Ethytnilestradiol Drosperidona/Ethyniestradiol</brief_title>
	<detailed_description />
	<mesh_term>Metrorrhagia</mesh_term>
	<mesh_term>Dienogest</mesh_term>
	<criteria>Sign , initial date inform consent form ; Female patient , child bear potential , age 18 35 year ; Have indication receive progesterone estrogenbased low oral hormone treatment least 7 cycle ( approximately 7 month ) birth control ; Be able comply study protocol ; Show normal result cervicalvaginal cytology conduct 3 month study enrollment willing repeat screen visit test , result must also normal ; Be willing use one study drug Is pregnant breastfeeding , suspect plan get pregnant ; Patients currently use oral contraceptive drospirenone 3 mg/ ethynilestradiol 30 mcg dianogest 2 mg/ ethynilestradiol 30 mcg . Have history gynecologic surgery hysterectomy , total oophorectomy tubal ligation ; Smoke 10 cigarette day ; Have severe comorbidities ( investigator 's criterion ) , include bowel inflammatory disease Have hypertension , show least one follow condition : Systolic pressure &gt; 140 mm Hg diastolic pressure &gt; 90 mm Hg sit position ; Current use pharmacological treatment hypertension ; Show history currently venous arterial thromboembolism ; History breast genital cancer ; Have obesity ( BMI &gt; 30 kg/m2 ) ; Have liver disease change lab value ; Currently dysplasia malignancy cervicalvaginal cytology ; Concomitantly use CYP3A4 metabolize drug drug cause drug interaction study drug ; History abortion one ( 1 ) month study enrollment ; History childbirth breastfeed 3 month study enrollment ; Have hypersensitivity study drug component ; Patients longterm disability , undergone major surgery surgery leg major traumatism last 6 month ; Have current diagnosis sexually transmitted disease ; Have use injectable hormone 3 month study enrollment ; Have use hormone implant 6 month study enrollment ; Have participate another clinical trial last 12 month .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>March 2012</verification_date>
</DOC>